Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — Five of the most vulnerable Democrats in the Senate on Tuesday publicly renewed their push to let Medicare negotiate lower drug prices — one of the first signals from the new Congress that key Democrats hope to campaign again on the popular policy in the 2022 midterm elections.

Every lawmaker has leverage in the narrowly divided Senate, but this group will especially have leadership’s ear as they fight to hold onto their seats to preserve Democrats’ perilous majority in the 2022 midterm elections. Three of the lawmakers are on the Finance Committee, which will be responsible for crafting the drug pricing policy that will be included in Democrats’ behemoth budget bill.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment